Single-domain antibody fragments derived from heavy-chain antibodies: a review
نویسندگان
چکیده
منابع مشابه
Potent enzyme inhibitors derived from dromedary heavy-chain antibodies.
Evidence is provided that dromedary heavy-chain antibodies, in vivo-matured in the absence of light chains, are a unique source of inhibitory antibodies. After immunization of a dromedary with bovine erythrocyte carbonic anhydrase and porcine pancreatic alpha-amylase, it was demonstrated that a considerable amount of heavy-chain antibodies, acting as true competitive inhibitors, circulate in th...
متن کاملBeta-lactamase inhibitors derived from single-domain antibody fragments elicited in the camelidae.
Small, soluble single-domain fragments derived from the unique variable region of dromedary heavy-chain antibodies (VHHs) against enzymes are known to be potent inhibitors. The immunization of dromedaries with the TEM-1 and BcII beta-lactamases has lead to the isolation of such single-domain antibody fragments specifically recognizing and inhibiting those beta-lactamases. Two VHHs were isolated...
متن کاملLactobacilli expressing variable domain of llama heavy-chain antibody fragments (lactobodies) confer protection against rotavirus-induced diarrhea.
BACKGROUND Rotavirus-induced diarrhea poses a worldwide medical problem in causing substantial morbidity and mortality among children in developing countries. We therefore developed a system for passive immunotherapy in which recombinant lactobacilli constitutively express neutralizing variable domain of llama heavy-chain (VHH) antibody fragments against rotavirus. METHODS VHH were expressed ...
متن کاملRetroviral Transduction of Fluonanobody and the Variable Domain of Camelid Heavy-Chain Antibodies to Chicken Embryonic Cells
Background: Single domain antibodies from camel heavy chain antibodies (VHH or nanobody), are advantages due to higher solubility, stability, high homology with human antibody, lower immunogenicity and low molecular weight. These criteria make them candidates for production of engineered antibody fragments particularly in transgenic animals. Objective: To study the development of transgenic ch...
متن کاملنانوبادی و کاربردهای درمانی آن
Background and purpose: Monoclonal antibodies market has grown since approval of Muromonab-CD3 (trade name Orthoclone OKT3) in 1986 as immuno- suppressor. Nevertheless, the undesirable effects of these large specific biomolecules calls for further attempts for more effective alternatives. Variable domain of heavy chain (VHH) are the smallest antibody fragments called Nanobody (Nb), derived...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Veterinární Medicína
سال: 2012
ISSN: 0375-8427,1805-9392
DOI: 10.17221/6336-vetmed